Mobile
Recherche simple
Recherche avancée
Recherche multicritère
Qui sommes-nous ?
Connexion
Inscription
French
English
Kusajili – Centralise les essais cliniques mondiaux
Résultat
de votre recherche span> par promoteur : Pfizer Inc 235 East 42nd Street, New York, NY10017
Femme et Homme Max 99 ans
Pfizer Inc 235 East 42nd Street, New York, NY10017
MAJ Il y a 5 ans
A PHASE II PROSPECTIVE, RANDOMIZED, MULTI-CENTER, DIABETIC MACULAR EDEMA DOSE RANGING, COMPARATOR STUDY EVALUATING THE EFFICACY AND SAFETY OF PF-04523655 VERSUS LASER THERAPY (DEGAS)
To evaluate efficacy of three dose levels of PF-04523655 versus laser in improving visual acuity in subjects with diabetic macular edema .
Pays
Aucun
Organes
Aucun
Spécialités
Aucune
Essai clos aux inclusions
Plus d'informations
Femme et Homme Max 99 ans
Pfizer Inc 235 East 42nd Street, New York, NY10017
MAJ Il y a 5 ans
Phase 3, randomized, open-label study of the efficacy and safety of crizotinib versus pemetrexed/cisplatin or pemetrexed/carboplatin in previously untreated patients with non-squamous carcinoma of the lung harboring a translocation or inversion event involving the anaplastic lymphoma kinase (ALK) gene locus
To demonstrate that crizotinib (Arm A) is superior to first-line chemotherapy (pemetrexed/cisplatin or pemetrexed/carboplatin) (Arm B), in prolonging PFS in patients with advanced nonsquamous NSCLC ...
Pays
Aucun
Organes
Aucun
Spécialités
Aucune
unknown
Plus d'informations
Femme Max 99 ans
Pfizer Inc 235 East 42nd Street, New York, NY10017
MAJ Il y a 5 ans
A study investigating new drug PD-0332991 (PALBOCICLIB) for treatment of women with Hormone Receptor-Positive, Her2-Negative Metastatic Breast Cancer. Study has two groups: All patients will be treated with Fulvestrant (FASLODEX) and Goserelin (Zoladex). In addition, one group will receive PD-0332991 (PALBOCICLIB), the other group an inactive substance. Neither the patient nor the doctor will know the treatment group. The distribution into the groups will be random
To demonstrate the superiority of palbociclib in combination with fulvestrant (with or without goserelin) over fulvestrant (with or without goserelin) alone in prolonging investigator-assessed PFS in ...
Pays
Aucun
Organes
Aucun
Spécialités
Aucune
unknown
Plus d'informations
Femme et Homme Max 99 ans
Pfizer Inc 235 East 42nd Street, New York, NY10017 US
MAJ Il y a 5 ans
A Safety, Efficacy and Tolerability Trial of Pregabalin as Add-On Treatment in Pediatric and Adult Subjects with Primary Generalized Tonic-Clonic (i.e., Grand Mal) Seizures
To demonstrate superior efficacy of pregabalin compared to placebo for treatment of PGTC seizures as measured by the 28 day seizure rate. Safety objective: To assess the safety and tolerability o...
Pays
Aucun
Organes
Aucun
Spécialités
Aucune
unknown
Plus d'informations
Femme et Homme Max 99 ans
Pfizer Inc 235 East 42nd Street, New York, NY10017
MAJ Il y a 5 ans
An Investigational Drug, PF-02341066, Is Being Studied In Patients With Advanced Non-Small Cell Lung Cancer With A Specific Gene Profile Involving The Anaplastic Lymphoma Kinase (ALK) Gene
• To assess the anti-tumor efficacy of oral single agent PF-02341066 administered to patients with advanced NSCLC after failure of at least one line of chemotherapy and harbor a translocation or inver...
Pays
Aucun
Organes
Aucun
Spécialités
Aucune
unknown
Plus d'informations
Précédent
1
2